Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK
Executive Summary
Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S
You may also be interested in...
HPV Vaccine Review By CDC Cmte. Will Likely Consider Parental Choice
A review of vaccines for human papilloma virus by CDC's Advisory Committee on Immunization Practices will likely involve a discussion of societal issues surrounding the vaccination of adolescents
HPV Vaccine Review By CDC Cmte. Will Likely Consider Parental Choice
A review of vaccines for human papilloma virus by CDC's Advisory Committee on Immunization Practices will likely involve a discussion of societal issues surrounding the vaccination of adolescents
GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company